Register

Hematology

Pediatric Oncology   

Questions discussed in this category

Do you screen children with sickle cell disease for silent cerebral infarcts?
1 Answer available
How would you manage a CVST secondary to a traumatic brain injury with the presence of intracranial hemorrhage?
When would you consider using anticoagulation and for how long?
4 Answers available
Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?
1 Answer available
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
When would you initiate chronic therapeutic phlebotomy in a patient with erythrocytosis secondary to a high hemoglobin-oxygen affinity hemoglobinopathy?
1 Answer available
What is your target Hgb/Hct for women who are pregnant and have sickle cell disease in whom you are doing scheduled transfusions?
1 Answer available
How would you work up a patient with cutaneous mastocytosis?
Is a BM biopsy a must when there is skin involvement? If tryptase level is mildly elevated but less than 20 would you recommend a BM biopsy?
1 Answer available
Do you screen adults in your practice with sickle cell disease for silent cerebral infarcts?
The ASH 2020 guidelines have "recommended that adults with HbSS or HbSβ0 thalassemia be screened at least once for silent cerebral infarcts even ...
1 Answer available
Does the use of A+AVD versus ABVD affect your decision for consolidation RT for bulky Hodgkin lymphoma?
1 Answer available
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
1 Answer available
How do you manage steroid-refractory acute GVHD following allogeneic transplant?
What criteria do you use to define steroid-refractory disease? Does your management different by organ system involved - GI vs skin vs other?
1 Answer available
What antibiotic, antifungal and antiviral prophylaxis you give post CAR-T therapy, and what is the duration?
1 Answer available
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...
1 Answer available
How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...
2 Answers available
How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?
1 Answer available
How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?
1 Answer available
How do you approach autologous stem cell transplant in T-cell lymphomas/PTCL after induction chemotherapy with achievement of CR1?
NCCN says "consider autologous HCT" while retrospective data seems to support SCT in most histologies like AITL
1 Answer available
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?
1 Answer available
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
1 Answer available
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?
2 Answers available
For AML patients, when do you stop antiinfective agents?
At the time of count recovery or do you continue it throughout induction and consolidation?
1 Answer available
Are SCDs contraindicated in patients with acute DVTs?
Is it different than early mobility that we always encourage?
3 Answers available
For a patient with May-Thurner syndrome and DVT, would you recommend anticoagulation for 3-6 months or indefinitely?
4 Answers available
How would you approach treatment in a patient with Fanconi anemia and glioblastoma?
1 Answer available
Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?
NGS results are pending
1 Answer available
How do you manage hyperalgesia in patients with sickle cell disease?
1 Answer available
What is your practice regarding giving G-CSF to patients with ALL during initial induction?
The patient was recently diagnosed with pre-B ALL and is on day 10 of CALGB 10403. He is expectedly neutropenic as he received daunorubicin and vincri...
2 Answers available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
How do you manage mild Type 1 von Willebrand disease undergoing wisdom teeth removal?
Antifibrinolytic therapy alone +/- DDAVP?
1 Answer available
What additional testing is recommended with heterozygous HFE C282Y mutation whose ferritin is elevated and transferrin saturation percentage is at baseline?
Ferritin >2200, TSAT >80%
2 Answers available
What is your preferred formulation of parenteral iron?
There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...
1 Answer available
Would you extend the duration of anticoagulation in patients with a provoked DVT, but evidence of residual clot at 3 months?
While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...
3 Answers available
For pediatric patients with localized diffuse large B-cell lymphoma being treated per COG ANHL 1131 in group B, do you feel it is necessary to complete all lumbar punctures with IT therapy?
2 Answers available
How do you approach an ITP patient who responds very well to steroids but the response is short-lived?
How would you counsel the patient if he/she wants to continue on steroids?
3 Answers available
Do you use FVIII levels to differentiate between DIC and coagulopathy of liver disease?
Common thought is that FVIII may be used for differentiating coagulopathy in liver disease (normal to increased, from reduced clearance of VWF/FVIII) ...
4 Answers available
How do you approach anticoagulation in the setting of HIT and thrombocytopenia?
I.e. platelet count <30. Would your management change if HIT were only suspected rather than confirmed?  
1 Answer available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
What are your top takeaways from ASH 2023?
7 Answers available
How would you treat a woman with iron deficiency anemia, unresponsive to iron sulfate, and with allergic reaction to iron sucrose?
Anemia is secondary to menorrhagia. No gynecologic interventions were possible.
1 Answer available
Are there any possible scenarios where you would do phlebotomies for heterozygous hemochromatosis?
1 Answer available
How do you dose apixaban in patients with CrCl <30 mL/minute?
1 Answer available
How soon after CAR T-cell therapy can salvage radiation be delivered?
3 Answers available
What is your approach to cancer patients who inquire about alternative or complementary treatments?
8 Answers available
What is your approach to using medications that can cause bone marrow suppression in SLE patients who have persistent leukopenia?
3 Answers available
Would you anticoagulate a patient with splenic infarctions in the setting of CMV viremia?
If so, for how long? 
1 Answer available
Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?
2 Answers available
How do you interpret a low VWF activity/antigen ratio, when both activity and antigen levels are above 50%?
E.g. Normal F8, VWF activity ~50%, VWF antigen ~100%, ratio 0.5 sent in a patient with positive bleeding history Is there any clinical significance t...
1 Answer available
What is the ideal period to wait until curative surgery for patients with acute pulmonary embolism and solid malignancy?
Specifically, asymptomatic subsegmental PE diagnosed within a month from planned bilateral mastectomy for breast cancer. 
1 Answer available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
1 Answer available
What is the role of radiation therapy in recurrent Rosai-Dorfman disease after surgical resection, which manifests as many cutaneous lesions on the arms and buttocks?
Does the fact that the patient is on methotrexate alter your choice?
2 Answers available
Do you recommend continued PCR testing in a CML patient who underwent allogeneic stem cell transplantation with an identical match about 20 years ago? 
1 Answer available
How do you approach the management of GVHD prophylaxis in the setting of severe infection?
1 Answer available
How do you approach a persistently elevated mean platelet volume and immature platelet fraction in an otherwise healthy patient with a normal platelet count?
Provided that the platelet count is normal, do you usually consider this to be a potential erroneous result or do you pursue additional workup for RBC...
1 Answer available
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
1 Answer available
When should you use caplacizumab in the treatment of acute TTP patients?
1 Answer available
Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?
1 Answer available
Is there a correlation between spleen size and degree of thrombocytopenia?
1 Answer available
What would your next line of treatment be for a patient with Hb SC with history of recurrent VOC and new bone infarct who is already on hydroxyurea and phlebotomy?
Hb at goal of 9-10
1 Answer available
How would you adjust the steroid dose for steroid-induced psychosis in a patient being treated for secondary HLH with the HLH-94 protocol?
1 Answer available
Is it true that a ferritin above 200 essentially rules out iron deficiency?
Does this hold true when the patient has significant inflammation? 
1 Answer available
How would you approach microcytosis without anemia with high TSAT and ferritin?
How often do you see non transfusion-dependent thalassemia and how do you approach the treatment?
1 Answer available
How is transferrin saturation a reliable indicator for any parameter if serum iron is not reliable?
Although TIBC is negative acute phase reactant, would it be a better indicator of iron deficiency (in combination with ferritin)?
1 Answer available
What are common indications for ordering NGS of peripheral blood?
Would a negative NGS eliminate the possibility of MDS? Is bone marrow biopsy indicated in a patient with pancytopenia with a negative NGS panel?
1 Answer available
Should testing for genetic causes of HLH be performed in all patients with MAS or secondary HLH regardless of the patient's age?
2 Answers available
What is your practice for work up and treatment of incidental splenic infarcts with or without splenomegaly in patients without sickle cell disease?
1 Answer available
For patients with microcytosis MCV 75-79 and normal Hb, low TIBC, and normal ferritin do you always rule out thalassemia?
What else would you consider in your differential?
5 Answers available
Based on recently published data from COG ANHL12P1, how will you use crizotinib in pediatric and AYA patients with ALK+ anaplastic large cell lymphoma?
How would the risk of VTE associated with crizotinib affect your decision? Should we consider using crizotinib in combination with brentuximab?
3 Answers available
How do you approach very treatment-refractory ITP?
Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.
1 Answer available
How do you approach dosing of anakinra in MAS?
1 Answer available
How do you manage severe cytarabine syndrome in AML patients, manifesting as severe hypotension, fevers, rash, and myalgias?
Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?
1 Answer available
For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?
Would you consider low dose indefinite anticoagulation in any scenario? Any difference in approach between hematological malignancy and solid tum...
1 Answer available
In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?
No prior thrombosis; no family history of thrombosis. As per endocrine, the only useful therapy for the osteoporosis is estrogen. 
1 Answer available
How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
How is this entity distinct from other secondary HLH entities? 
2 Answers available
Do you routinely use G-CSF post-allogeneic transplant for non-haploidentical transplants?
1 Answer available
What is your approach to treatment of infection-triggered HLH that does not respond to treatment of the underlying infection?
2 Answers available
In the setting of secondary HLH associated with initial diagnosis of lymphoma, would you adjust steroid dose and type to account for differences in HLH and lymphoma treatment protocols?
1 Answer available
When should I consider anticoagulation in an unprovoked upper extremity superficial venous thrombosis?
Would it change your management if the thrombus was symptomatic? Or if larger >3 cm?
1 Answer available
Can Hodgkin-like PTLD be treated with Rituximab and weaning of immunosuppression, or is Hodgkin-directed chemotherapy necessary for cure?
1 Answer available
What are the best labs to trend improvement in HLH?
1 Answer available
Do you check asparaginase levels for all patients receiving receiving E. coli-derived products, or only in certain clinical situations?
1 Answer available
How do you mitigate 6-MP-induced GI toxicity in pediatric and AYA patients with leukemia?
2 Answers available
What is your approach to further work-up and management of neutropenia in patients with SLE/RA overlap?
For example, a patient with a bone marrow biopsy that shows normocellular bone marrow. Prior management with leflunomide and HCQ with neutropenia attr...
2 Answers available
What is your approach to treating a young adult with severe aplastic anemia unresponsive to steroids and TPO-mimetics?
What would your next line therapy be? If the patient had no matched related or unrelated donors, would you consider haploidentical transplant?
1 Answer available
Would you use a matched sibling donor with a germline heterozygous BRCA1 mutation for stem cell transplant?
Presuming there are no matched unrelated donors.
1 Answer available
In a patient hospitalized for several days with a refractory pain crisis would you ever consider transfusion, either simple or possibly exchange in an attempt to get the patient over the crisis?
2 Answers available
Do you recommend hydroxyurea in patients with sickle cell disease with hereditary persistence of fetal hemoglobin who have recurrent vaso-occlusive crises requiring hospital admission?
If hydroxyurea modifies the course of sickle cell disease by increasing fetal hemoglobin, is there any benefit to using it in patients with fetal hemo...
1 Answer available
When do you refer AYA patients with newly diagnosed severe aplastic anemia for transplant?
Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?
2 Answers available
Would you use PCC for clotting factor repletion in acute life threatening hemorrhage in a patient with elevated INR from coagulopathy of liver disease?
2 Answers available
For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?
What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?
1 Answer available
How do you approach a patient with chronic low ADAMTS13 activity and low level of inhibitor without signs of thrombocytopenia or hemolysis?
ADAMTS13 level <5% Inhibitor level <1
1 Answer available
How do you explain TTP to patients?
1 Answer available
When patients develop headaches from luspatercept, do they tend to improve over time?
1 Answer available
How can oncologists be more collaborative with palliative care physicians?
How can these interactions be improved? 
1 Answer available
Would you consider TPO mimetics for chemotherapy induced thrombocytopenia that persists despite dose reductions?
1 Answer available
Do you repeat images in patients with venous thrombosis to inform decision about duration of anticoagulation?
E.g. pulmonary embolism, portal vein thrombosis, cerebral venous sinus thrombosis
2 Answers available
Do you recommend starting an antiplatelet for primary prophylaxis in post splenectomy thrombocytosis given there is some increased risk of venous thrombosis?
If so, what platelet count threshold would you use? Would age impact your decision? Would you do a bone marrow to rule out primary MPD in adults if th...
1 Answer available
What is the optimal age at which a patient with sickle cell disease should undergo allogeneic stem cell transplant?
2 Answers available
What is your ferritin threshold to prescribe iron to female adolescent athletes who have symptomatic iron deficiency without anemia?
What is the ideal approach for female adolescent athletes if they have complaints of fatigue and dizziness and are diagnosed with mild iron deficiency...
1 Answer available
Would you recommend adding a TKI to a pediatric regimen for a AYA B-ALL patient with IKZF1 mutation?
1 Answer available
How do you perform fertility counseling for a patient with a duplication of one of the alpha genes and their partner who has a beta chain point mutation?
That is, extra copy of one of the alpha genes resulting in an atypical alpha thalassemia for the patient, and beta thalassemia heterozygous carrier fo...
1 Answer available
What precautions do you take prior to CABG in a patient with sickle cell trait?
Please comment on temperature recommendations and role of exchange transfusion. 
1 Answer available
In sickle cell patients with continued pain crises despite hydroxyurea, how do we sequence the use of newer agents?
While L-glutamine has minimal side effects and would likely be added after hydrea, how do you decide between the use of voxelotor and crizanlizumab?
3 Answers available
How do you approach low to moderate titer of APLS when working up unprovoked DVT if it is persistent on repeat testing?
4 Answers available
Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?
2 Answers available
Do you switch from imatinib to another TKI in patients with chronic phase CML who develop renal insufficiency?
There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?
2 Answers available
Do you screen for VWD in all women with menorrhagia severe enough to cause iron deficiency anemia?
3 Answers available
How should elevated PT of unclear etiology and significance be evaluated?
In the absence of concerning bleeding or thrombosis, family history of coagulopathy, current anticoagulant use, or malnutrition
2 Answers available
Do you typically see peripheral neuropathy in patients with castleman syndrome?
2 Answers available
How would you approach a low to moderate titer of one of the APLS antibodies in a patient with a strong family history but no personal history of thrombosis?
Although testing was not indicated, what do u do with these results? Other hypercoagulability work up negative
2 Answers available
What are your top takeaways from ASH 2022?
8 Answers available
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
2 Answers available
Would you discontinue anticoagulation in patients with antiphospholipid antibody syndrome, who have a remote history of thrombotic events and are now negative for pathogenic antiphospholipid antibodies?
Would the answer differ if the index event was arterial vs venous? 
3 Answers available
How do you advise patients with sickle cell disease on contraception?
Do you advise against combination OCPs?
1 Answer available
Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?
1 Answer available
How would you approach management of bleeding risk and factor VIII replacement in a patient with severe hemophilia A undergoing stem cell transplant?
1 Answer available
What is your perioperative approach for a patient with severe hemophilia?
What type, dosage, and duration of treatment do you use? How does your practice change when there is an inhibitor?
1 Answer available
How would you work up a mildly neutropenic patient (ANC >800) with family history of neutropenia and personal history of occasional mouth sore?
What are indications to order gene mutation studies (e.g. ELANE) and how would it help the patient?
1 Answer available
How do you manage prophylactic antimicrobial medications in patients who undergo ATG/cyclosporine/eltrombopag induction for severe aplastic anemia?
What would you recommend within the first year after ATG and thereafter if still maintained on cyclosporine?
1 Answer available
What is your approach to BK hemorrhagic cystitis not responding to cidofovir?
1 Answer available
Which patients with acute promyelocytic leukemia do you consider maintenance after completing consolidation?
1 Answer available
How do you work up a young patient with increasing ferritin and normal TSAT without infectious, inflammatory, or liver disorders?
Ferritin uptrending >1000, no additional lab abnormalities. HFE wildtype. Too young for age-appropriate cancer screening. Asymptomatic except fatig...
1 Answer available
In a patient with Type I von Willebrand disease with history of VTE and heavy menses, would tranexamic acid be a treatment option?
Is thrombotic risk too significant? Patient failed OCPs.
3 Answers available
Do you stop hydroxyurea or switch to an alternative therapy in a male patient with controlled Hb SC disease who is interested in having children?
2 Answers available
What is the treatment of choice for mixed phenotype ALL?
What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?
1 Answer available
At what ferritin threshold would a patient with anemia of inflammation or malignancy no longer benefit from iron supplementation for functional iron deficiency?
For example, if TSAT is less than 20% but ferritin is over 200. 
1 Answer available
Do you recommend continuous antibiotic prophylaxis for patients on complement inhibitors such as eculizumab?
Do you just use antibiotic prophylaxis if therapy is started prior to meningococcal vaccination?
3 Answers available
Should post-transplant cyclophosphamide be utilized for all matched unrelated donor peripheral blood stem cell transplants for hematologic malignancy?
If not, how do you choose GVHD prophylaxis regimen? Is there a preference?
2 Answers available
Based on recent data would you consider adding ATRA to low dose rituximab for steroid refractory ITP?
Wu et al., PMID 34665865 
1 Answer available
How would you approach cytopenias 5 weeks after initial dosing in a young patient with MDS treated with Azacitadine as a bridge to transplant?
E.g. would you dose-reduce or continue at same dose? Baseline ANC was in the normal range
1 Answer available
Is there a role for IL2-receptor antagonists and TNF-alpha inhibitors in cytokine release syndrome as a complication of CAR-T or immunotherapy?
1 Answer available
When do you stop trying to eradicate an acquired factor VIII inhibitor?
Patient with high titer acquired FVIII inhibitor with no causative etiology.  Bleeding is well-controlled on emicizumab, but inhibitor has failed...
3 Answers available
What recommendations do you have for a transgender female patient with history of prothrombin gene mutation who is interested in starting gender affirming hormone therapy?
The patient has no personal history of VTE, but has positive family history of VTE.  Any prophylactic anticoagulation options? How would manage...
1 Answer available
Do you hold IV iron in the setting of active infection?
1 Answer available
Do you routinely send NGS testing from bone marrow samples in patients with unexplained cytopenia or cytoses?
For instance, if clonal hematopoiesis of indeterminate potential (CHIP) suspected 
1 Answer available
How would you approach an early stage II unfavorable Hodgkins lymphoma following 6 cycles ABVD with persistent Deauville 5 with negative biopsy?
iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.
1 Answer available
In patients with severe hemophilia A on emicizumab for prophylaxis, in case of noncompliance leading to a lapse of more than 2-3 months off therapy, do you reload with emicizumab?
1 Answer available
When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?
1 Answer available
In patients who develop a VTE, what conditions do you consider as persistent, provoking risk factors, and at what point are they controlled enough to stop anticoagulation?
I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...
1 Answer available
What are your recommendations for a male patient who was recently started on imatinib and wants to conceive?
4 Answers available
How soon do you anticipate response to cyclosporine in red cell aplasia and what cyclosporine trough levels do you target?
1 Answer available
How would you work up and manage persistent lymphopenia in an asymptomatic patient?
ALC<200
1 Answer available
Do you consider travel as a risk factor for DVTs in the absence of any other underlying predisposing factors?
i.e. long car rides or plane rides
1 Answer available
What is the benefit of cytoreduction with Hydroxyurea for patients with newly diagnosed chronic phase CML with a WBC count >100 prior to the initiation of a TKI?
1 Answer available
Do you offer iron supplementation to a non-anemic adolescent athlete with a low ferritin?
1 Answer available
Is an elevated CRP an expected finding in an otherwise healthy patient with hemoglobin S - alpha thalassemia?
CRP 39 mg/L (normal < 10) and normal ESR
1 Answer available
What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
Which, if any, young/fit intermediate-risk AML patients would you not offer allogeneic transplant to in MRD- CR1?
1 Answer available
Does normal methylmalonic acid levels absolutely rule out vitamin B12 deficiency?
1 Answer available
How do you define bulky disease for Hodgkin's lymphoma which is outside the mediastinum?
Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...
1 Answer available
In a patient with sickle cell disease on hydroxyurea who is planning to have a family, for how long should they be off the drug before trying to conceive?
1 Answer available
How do you manage a patient with a history of high-risk leukemia who has increasing loss of donor chimerism in the post-transplant setting in the absence of disease relapse?
How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...
1 Answer available
What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?
1 Answer available
At what platelet count would you feel comfortable dosing aspirin 81 mg for coronary artery disease in a patient with ITP?
Presuming strong indication for ASA - eg history of NSTEMI
1 Answer available
How do you counsel patients with elevated factor VIII levels for their thrombosis risk?
Should we stop checking factor VIII levels as part of thrombosis workup?
1 Answer available
How do you interpret elevations in antiphospholipid antibodies that are lower than Sapporo criteria?
(e.g. beta 2 glycoprotein IgM > 20 but <40)
2 Answers available
How has the virtual aspect of tumor boards impacted their educational quality in the Covid-19 era?
1 Answer available
Is there any benefit to transplant patients with Ph+ ALL who have achieved MRD-negativity?
1 Answer available
Would you give antithrombin concentrate for surgical VTE prophylaxis in case of congenital AT deficiency?
1 Answer available
What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?
1 Answer available
How do you manage patients who develop minor antigen antibodies and require multiple blood transfusions?
e.g. K, Fya, s, etc
1 Answer available
How do you manage a patient with sickle cell disease during pregnancy?
2 Answers available
How do you manage real-time release of pathology and radiology results to oncology patients following enaction of the CURES act?
1 Answer available
How do you approach IVIG replacement for pediatric patients with low IgG during treatment for hematologic malignancies?
Do you routinely check IgG levels during therapy, if not indicated by a study protocol?
1 Answer available
Do you routinely offer antiviral prophylaxis for patients receiving chemoimmunotherapy?
If so, what regimen do you utilize?
1 Answer available
Would you anticoagulate recurrent venous thromboembolism in a patient with Ehlers Danlos syndrome?
How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?
1 Answer available
Do you recommend the use of dexamethasone and anakinra as upfront treatment in a pediatric patient with secondary HLH (nonrheumatic) who is too ill to tolerate etoposide?
This type of etoposide sparing therapy has been previously described in a case series at https://pubmed.ncbi.nlm.nih.gov/32725881/
2 Answers available
Would you retry rituximab in steroid refractory warm autoimmune hemolytic anemia which responded to rituximab before?
Last rituximab 6 months ago
1 Answer available
Would you check vitamin B6 routinely in the work up of anemia?
1 Answer available
Are there best practices or data regarding the use of open notes among oncology patients?
What is the impact among patients and providers? Has your documentation been adjusted now that patients can readily review?
2 Answers available
How do you approach heparin management in patients who have suprathetherapeutic Xa levels on minimal heparin?
1 Answer available
Do you repeat antiphospholipid antibody testing in a patient that previously met criteria for APLS?
If so, how long after diagnosis do you do so? 
1 Answer available
Does R-CHOP provide durable remission in low-risk pediatric Burkitt or Burkitt-like lymphoma?
2 Answers available
How do you interpret a Deauville score of 3 on PET when performing mid-treatment assessments in patients with Hodgkin lymphoma?
Are there situations in which a Deauville 3 would cause you to escalate therapy?
2 Answers available
When do you consider plasma exchange for multiorgan failure in a patient with sickle cell disease?
2 Answers available
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?
1 Answer available
Are there any situations you would recommend prophylactic anticoagulation for a patient with Factor V heterozygosity?
FVL heterozygotes are often treated similarly to the general population. Aside from avoiding other VTE risk factors, are there situations where prophy...
1 Answer available
When would you consider an umbilical cord blood transplant over a haploidentical transplant with post-transplant cyclophosphamide, or using a desensitization protocol for high donor-specific antibodies?
1 Answer available
In which platelet function disorders would you consider use of Novoseven as opposed to platelet transfusion?
Are there particular clinical scenarios that would affect your decision?
1 Answer available
Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?
2 Answers available
In a patient with a heterozygous prothrombin gene mutation who has COVID with minimal symptoms, do you recommend prophylactic and/or therapeutic anticoagulation?
1 Answer available
How do you manage drug-induced thrombocytopenia when the implicated drug is essential?
e.g. DITP from eptifibatide after a cardiac intervention
1 Answer available
For treatment of ITP, what would you add to dexamethasone to achieve the fastest recovery in a patient waiting for a procedure?
IVIG, TPO, or other agents?
1 Answer available
When would you consider stopping chronic transfusion therapy in a sickle cell patient with history of abnormal TCDs but no stroke?
1 Answer available
How do you approach relapsed idiopathic HLH?
2 Answers available
How will you use Pola-R-CHP in the frontline treatment of DLBCL?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...
2 Answers available
What are contraindications for growth factors in patients with hematologic malignancies?
2 Answers available
Do you routinely check platelet counts after COVID-19 vaccines in patients with chronic ITP?
1 Answer available
How do you counsel male-to-female transgender patients on the VTE risk of hormonal therapy?
1 Answer available
How do you manage a patient with superficial venous thrombosis with close proximity (<3 cm) to deep veins and an inherited thrombophilia ?
Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk? 
1 Answer available
Is there experience/reports of using voxelotor in sickle cell patients who are Jehovah Witnesses with few crises but who have fatigue and/or dyspnea?
Also is there value in using voxelotor for the purpose of reducing hemolysis, and if so what parameters do you use to determine when to initiate voxel...
1 Answer available
Is there a role for radiation therapy in the treatment of a lymphoproliferative disorder involving the orbit?
If so, what dose and fractionation would you recommend?
4 Answers available
What is the typical time course of cytopenias after CAR-T therapy, and how do you treat them?
1 Answer available
What is your preferred approach for patients with anti-phospholipid syndrome with recurrent thrombosis on coumadin and LMWH?
1 Answer available
How would you approach moderate neutropenia (ANC < 1000) in a solid organ transplant recipient?
Is there a particular sequence you would adjust contributing antirejection or antimicrobial medications? Is the use of G-CSF appropriate and at what c...
2 Answers available
What is your escalation strategy for chronic GvHD?
How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?
1 Answer available
What is the role of hydroxyurea in variant sickle cell genotypes?
Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...
2 Answers available
How do you diagnose sickle hepatopathy?
1 Answer available
In what circumstances would you give G-CSF to a patient with severe neutropenia and HLH?
1 Answer available
How do you approach conversations regarding discontinuation of transfusions in patients with advanced hematologic malignancies who are otherwise appropriate for hospice?
Are there other supportive care interventions that would otherwise be covered by hospice?
1 Answer available
What is your approach to a patient with positive antiphospholipid antibodies who otherwise do not meet clinical criteria for APS?
What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...
3 Answers available
Do you utilize D-dimer to inform anticoagulation duration in the treatment of VTE?
Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...
2 Answers available
When is a lumbar puncture indicated in a lymphoma staging work up for a pediatric or AYA patient?
Is an LP only recommended in the setting of particular subtypes of lymphoma or symptoms of CNS disease?
1 Answer available
How would you manage VTE in a patient with bleeding disorder such as hemophilia?
Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?
1 Answer available
What regimen would you offer a young patient with T-cell ALL who recurred a short time after allo-transplant and was initially treated with CALGB10403?
Especially with the current drug shortage of nelarabine.
2 Answers available
Would you start TKI therapy in a patient with new diagnosis of T-ALL without BCR-ABL gene rearrangement on FISH but found to have very low level p190 transcript on RT-PCR?
1 Answer available
How do you approach management of sickle cell patients who mistrust Western medicine and prefer naturopathic therapies?
While building a trusting patient-physician relationship, what therapies could be discussed that may be aligned with naturopathic medicine? (i.e. L-gl...
1 Answer available
What is the maximum pRBC volume you can transfuse when performing a manual exchange transfusion in an adult-sized patient with sickle cell disease?
1 Answer available
How do you approach treatment of vasculitis in a sickle cell disease patient?
There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...
1 Answer available
Do you use premedications (acetaminophen, diphenhydramine) before pRBC and plt transfusions to prevent febrile nonhemolytic transfusion reactions and allergic reactions?
Does manipulation of blood products (leukoreduction, irradiated) affect your approach? There is growing evidence that routine premedication (at least ...
1 Answer available
Under what circumstances would you consider anticoagulation in a young female patient with persistently elevated factor XI activity?
While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...
1 Answer available
Are there any special considerations when evaluating patients with non-malignant hematologic or immunodeficiency disorders for allogeneic transplant?
Are there major differences in standard conditioning and/or GVHD prophylaxis regimens utilized? Does the non-relapse mortality different significantl...
3 Answers available
How would you optimally manage a patient with a MDS/MPN overlap syndrome who has both transfusion-dependent anemia and marked thrombocytosis?
Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?
1 Answer available
Should assessing for a MTHFR mutation be part of the thrombophilia evaluation in a patient presenting with a thrombus?
1 Answer available
How would you approach immunosuppression for patients with severe aplastic anemia who are not transplant or ATG candidates?
Such as patients who are frail, elderly, renally impaired? Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...
1 Answer available
How long do you continue caplacizumab in relapsed refractory TTP?
How often do you monitor ADAMTS-13 levels off therapy?
1 Answer available
Are there any reasons to consider a prolonged course of steroids with taper over a shorter course of pulsed steroids in the treatment of ITP?
For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?
1 Answer available
What strategies have you found to be most effective in engaging PCPs in a primary-care or shared-care model of survivorship for pediatric and AYA patients who will receive ongoing care in their communities away from their primary oncology treatment site?
In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients. 
1 Answer available
With new data showing similar outcomes of mismatched unrelated donor and haploidentical related donor allogeneic transplants using post transplant cyclophosphamide, how does one decide which donor is optimal?
If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...
1 Answer available
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
1 Answer available
How would you approach chronic isolated severe non-cyclic neutropenia with negative bone marrow and rheumatologic work-up?
Is there a role for empiric antibiotics if there is history of opportunistic infection?
1 Answer available
What further genetic testing would you perform on a pediatric patient with cyclic neutropenia who is negative for the most common associated mutations?
With a strong family history
1 Answer available
In patients with autoimmune cytopenias, is there any reservation for COVID vaccination?
While benefits outweigh known harms and limited data, do you worry about vaccination in patients with a history of or active autoimmune cytopenias (e....
1 Answer available
How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?
Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?
1 Answer available
How would you evaluate a patient with an isolated high RBC count but with a normal hemoglobin and hematocrit?
Would you consider this type of patient as having polycythemia?
2 Answers available
How do you approach transfusing a patient with sickle cell disease who has a history of hyperhemolysis?
0 Answers available
When (if ever) do you check for anti-platelet antibodies for workup of thrombocytopenia?
1 Answer available
Do you offer iron supplementation to a patient with iron studies that are normal (including normal ferritin) except for low iron saturation?
What is the potential differential diagnoses for low iron saturation?
1 Answer available
What additional testing, if any, should be performed for an adolescent patient with heavy menstrual bleeding and a negative von Willebrand disease evaluation?
1 Answer available
When can defibrotide be discontinued before the 21-day treatment course is completed in a pediatric patient with SOS?
Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?
1 Answer available
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
3 Answers available
What workup do you perform to evaluate for underlying triggers/associated conditions in a pediatric patient with autoimmune hemolytic anemia?
1 Answer available
Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?
While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?
2 Answers available
How would you manage a patient with antiphospholipid syndrome in the setting of severe steroid-refractory thrombocytopenia?
Especially in a triple-positive patient with an acute ischemic stroke who may have urgency for anticoagulation with high bleeding risk and severe thro...
2 Answers available
How do you treat refractory cold agglutinin disease?
The patient who has not responded to steroids, rituximab/bendamustine, and splenectomy?
2 Answers available
How can healthcare providers better serve as allies of the sickle cell community?
Has your medical practice taken any steps either in community outreach or within the clinic to show support for this medically vulnerable population, ...
2 Answers available
When would you recommend using a DOAC in a pediatric patient with VTE?
3 Answers available
What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?
2 Answers available
Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?
2 Answers available
How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?
1 Answer available
How would you approach the treatment of patients with von Willebrand disease or hemophilia A previously managed with intranasal DDAVP during the recall?
During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?
1 Answer available
What is your preferred oral iron formulation and dosing for treatment of iron deficiency anemia?
Are most places administering oral iron as once daily or every other day dosing due to upregulation of hepicidin receptors following oral iron adminis...
1 Answer available
How many years of oral antibiotics prophylaxis do you recommend for a teenager with hereditary spherocytosis post-splenectomy?
There is no uniform guideline in the literature. AAP recommends until 5 years old or 1-year post-splenectomy. Some for 5 years post-splectomy.
2 Answers available
Is there a role for G-CSF treatment for SLE patients with persistent neutropenia?
1 Answer available
How do you counsel patients who are candidates for a clinical trial regarding their options?
Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?
2 Answers available
In which patients with atypical HUS would you consider eculizumab discontinuation?
Given the high cost of eculizumab, are there patient characteristics that inform which patients, if any, should be on indefinite therapy versus a time...
2 Answers available
How do you manage a delayed hemolytic transfusion reaction in a patient with sickle cell disease?
How do you manage an uncomplicated DHTFR versus a hyperhemolysis?
1 Answer available
What is your threshold for pursuing bone marrow biopsy in a lupus patient with cytopenias?
2 Answers available
What is the target ferritin level for patients with hereditary hemochromatosis and signs of end-organ damage?
For example, a patient with hypogonadism unless it matters which organ is involved. Are other markers of iron storage useful in guiding therapy?
2 Answers available
How do you approach anticoagulation in patients with catastrophic antiphospholipid syndrome and thrombocytopenia?
1 Answer available
When would you consider splenectomy or other immunosuppressive/cytotoxic therapy for steroid-refractory warm autoimmune hemolytic anemia?
For example, in a patient who is steroid-refractory, requiring regular transfusion, and has not had response to rituximab after several weeks.
1 Answer available
What are your thoughts on adding mycophenolate to steroids in the first line treatment of ITP based on the results of the FLIGHT trial?
Presented at ASH: FLIGHT trial
1 Answer available
For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?
1 Answer available
What are your indications for pursuing a rheumatologic workup in a pediatric patient with ITP?
If so, what additional testing do you send?  
1 Answer available
When would you perform a thrombophilia workup in a pediatric patient presenting with VTE?
1 Answer available
Is there a role for anti-neutrophil antibody testing in the workup of neutropenia?
If autoimmune neutropenia already suspected, is this test informative or unnecessary?
1 Answer available
Do hemoglobin S levels always correlate with SCD phenotype?
What is the lowest level you have seen with uncomplicated or complicated crises?
4 Answers available
How do you manage VTE in the setting of persistent severe thrombocytopenia?
Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?
3 Answers available
Is there any role for direct oral anticoagulants in the treatment of antiphospholipid syndrome?
What if this was "triple-negative" antiphospholipid syndrome?
2 Answers available
Would you start a patient with sickle cell disease and COVID-19 on prophylactic anticoagulation?
0 Answers available
When would you consider transplant for a patient with a bone marrow failure syndrome (FA, DC, etc.)?
2 Answers available
How would you treat a young patient with symptomatic Rosai-Dorfman disease who has recurrent, life-threatening pericardial and pleural effusions?
CT scans show omental and pelvic disease.
1 Answer available
How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?
Would you consider “bridging” therapy with something like an HMA?
1 Answer available
Do you recommend that children with sickle cell disease refrain from returning to school during the COVID-19 pandemic?
2 Answers available
During induction therapy for acute leukemia, when do you decide to discontinue the antimicrobial prophylaxis?
Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?
1 Answer available
What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?
1 Answer available
How would you manage a patient with severe aplastic anemia and a large PNH clone?
1 Answer available
For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?
Does acute leukemia sub-type affect your decision? 
1 Answer available
How would you evaluate a pediatric patient referred to rule out cancer due to an isolated significantly elevated vitamin B12 level?
Assuming CBC w/ different and complete metabolic panel are within normal limits, what (if any) further evaluation or management is needed?
0 Answers available
When during ALL induction therapy are you checking for MRD?
1 Answer available
Would you recommend prophylactic cranial irradiation (PCI) for a teenager with a T cell acute lymphoblastic leukemia in remission?
If so, what dose would you recommend? 
1 Answer available
How do you determine whether to treat a young adult with stage IA Hodgkin Lymphoma with the adult or pediatric treatment paradigm?
At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...
2 Answers available
Would you stop current immunosuppressive therapy or delay starting immunosuppressive therapy in a patient with aplastic anemia who has been infected with COVID-19?
2 Answers available
Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?
3 Answers available
Are patients with bleeding disorders receiving plasma-derived products at increased risk of acquiring COVID-19?
1 Answer available
Should patients with bleeding disorders increase their home supplies of clotting factors foreseeing a possible shortage of product availability due to COVID-19?
1 Answer available
How would you manage a patient with sickle cell disease who is infected with COVID-19?
1 Answer available
Do you have preferred regimens for young patients (<30 y/o) with early stage DLBCL?
Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approac...
1 Answer available
When would you consider treating a testicular relapse with definitive radiation in a child with ALL?
1 Answer available
What is the risk of breast cancer that you quote to young women with early stage Hodgkin's lymphoma receiving involved field/site radiation therapy?
We often see young women with favorable, early stage disease in the mediastinum who have had a complete response to chemotherapy. With current smaller...
1 Answer available
When would you consider testicular RT prior to TBI for BMT?
What dose do you recommend?
1 Answer available
How would you treat a pediatric patient with Stage IVB Hodkin lymphoma who still has persistent PET+ disease after dose-escalated chemotherapy?
After ABVE-PC X4 and Ifos/vinorelbine x 2 per AHOD 0831 (and is unable to have these sites biopsied), what dose would you treat to and what volume wou...
1 Answer available
Do you omit consolidative RT in pediatric patients with intermediate risk, non-bulky Hodgkin lymphoma who have a rapid early response to chemotherapy?
Are the results of AHOD0031 practice changing?
1 Answer available
Is it acceptable to treat pediatric Hodgkin's lymphoma with an involved nodal field outside the setting of a clinical trial?
1 Answer available
Is it preferable to simulate pediatric Hodgkin's lymphoma patients with arms up or akimbo?
It seems that with the arms up, you get better lung blocking but with arms akimbo, you might have a lower dose to the humeral head. 
1 Answer available


Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10
Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.
Practical radiation oncology, 2015
Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Cancer, 2004-08-15
The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation.
Br. J. Haematol., 2003-11-01
Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia.
Br. J. Haematol., 1998-08-01
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Cancer, 1990-11-15
Testicular relapse in children with acute nonlymphoblastic leukemia.
Radiother Oncol, 1990-01-01
Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience.
Medical and pediatric oncology, 1981
The cytosine arabinoside (Ara-C) syndrome.
Int. J. Radiat. Oncol. Biol. Phys., 2017-01-01
Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
Cancer, 1994-01-01
Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Childrens Cancer Group.
Med. Pediatr. Oncol.,
Gonadal and sexual function in men treated for childhood cancer.
Arch. Dis. Child.,
Survival and endocrine outcome after testicular relapse in acute lymphoblastic leukaemia.
Pediatric blood & cancer, 2018-05
Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.
Br. J. Haematol.,
PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia.
Fertil. Steril., 2013 Sep 05
Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.
The New England journal of medicine, 2020 Apr 22
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Blood,
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
J. Clin. Oncol., 2019 Sep 10
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Acta Paediatr., 2020 Mar 23
Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults.
American journal of hematology, 2018-08
Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Blood, 2019-04-04
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Am. J. Hematol., 2019 Nov 19
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01
Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20
Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.
J. Clin. Oncol.,
Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
QJM, 2013 Feb 27
The pathophysiology of elevated vitamin B12 in clinical practice.
Blood, 2021 Apr 01
Real-world experience with caplacizumab in the management of acute TTP.
The New England journal of medicine, 2007-01-25
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Haematologica, 2020
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
Nature, 2019-03
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Blood, 2018 May 02
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Leuk Lymphoma, 2019 Dec 26
Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman Disease).
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).
Blood, 2018 Jul 12
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Ann. Intern. Med., 2019 Oct 15
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Blood Transfus, 2018 Oct 24
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
J Thromb Haemost, 2018 May 08
Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.
, 2016 Apr 26
Lymphoid hyperplasia of the orbit and ocular adnexa: A clinical ​pathologic review.
American journal of clinical oncology, 1992-10
Radiotherapy of lymphoproliferative diseases of the orbit. Surveillance of 65 cases.
The New England journal of medicine, 2017-02-02
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Blood, 2009 Nov 10
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Clin Lymphoma Myeloma Leuk, 2017 Mar 07
Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.
American journal of hematology, 2011-10
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia.
The American journal of medicine, 2017-12
Results of the First American Prospective Study of Intravenous Iron in Oral Iron-Intolerant Iron-Deficient Gravidas.
American journal of hematology, 2018-05
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Am J Hematol, 2020 Jun 29
A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.
Am J Hematol, 2019 Sep
A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
Am J Hematol, 2019 Sep
Single total dose infusion of ferumoxytol (1020 mg in 30 minutes) is an improved method of administration of intravenous iron.
Am J Hematol, 2018 Jun
Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia.
JAMA,
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
N Engl J Med,
Sickle Cell Disease.
BMJ, 2008 May 20
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
Circulation,
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
The journal of allergy and clinical immunology. In practice, 2017
Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.
Journal of thrombosis and haemostasis : JTH, 2018-06-07
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.
American journal of hematology, 2008-08
Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population.
Blood, 2010-07-22
How I treat hemochromatosis.
Am J Gastroenterol,
ACG Clinical Guideline: Hereditary Hemochromatosis.
Blood, 2017-07-20
Eculizumab cessation in atypical hemolytic uremic syndrome.
Clin J Am Soc Nephrol, 2016 Oct 31
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Blood, 2020 Dec 03
Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study.
Rheumatol Int, 2019 Apr 30
Indications for bone marrow examinations in rheumatology.
Clin Exp Rheumatol, 2012 Sep 25
Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations.
Wien Klin Wochenschr,
[Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].
J Rheumatol, 2006 Jul 01
Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.
Semin Arthritis Rheum,
Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor.
Lancet Haematol, 2019 Nov 05
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Am J Clin Nutr, 2020 Aug 25
Iron supplementation in infants: a reflection on hepcidin and fractional iron absorption.
Am J Prev Med,
Population estimates of sickle cell disease in the U.S.
J Natl Med Assoc,
Health-related stigma in young adults with sickle cell disease.
J Adv Nurs, 2015 Sep 09
Perceptions of young adults with sickle cell disease concerning their disease experience.
Issues Ment Health Nurs, 2018 Apr 13
Stigma of Sickle Cell Disease: A Systematic Review.
JAMA Netw Open, 2020 May 01
Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care.
Emerg Infect Dis, 2020 Jul 08
Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020.
Blood, 2013-12-05
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.
Blood Adv,
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.
Blood,
Five hematologic tests and treatments to question.
Blood, 2013 Sep 19
Management of the refractory aplastic anemia patient: what are the options?
The Lancet. Haematology, 2015-09
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
Haematologica, 2017-07
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.
Thrombosis, 2013
A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.
Thrombosis journal, 2023 Oct 26
The clinical application of venous ultrasound in diagnosis and follow-up of lower extremity deep vein thrombosis (DVT): a case-based discussion.
Blood, 2018 Jun 13
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.
Blood, 2010 Jul 15
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
American journal of hematology, 2019-04
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Blood Transfus, 2016 Dec 16
Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association.
American journal of hematology, 2023 May 12
An integrated therapeutic approach to sickle cell disease management beyond infancy.
The New England journal of medicine, 2014 Aug 21
More blood for sickle cell anemia?
Bone Marrow Transplant, 2019 Oct 01
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.
Front Immunol, 2020 Apr 03
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.
Haematologica, 2019 Oct 17
Bleeding disorders in adolescents with heavy menstrual bleeding in a multicenter prospective US cohort.
J Thromb Haemost,
Standardizing care to manage bleeding disorders in adolescents with heavy menses-A joint project from the ISTH pediatric/neonatal and women's health SSCs.
Transfus Med Rev,
Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.
Ann Intern Med,
The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Arthritis Rheumatol, 2019 Dec 26
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.
Seminars in hematology, 2013-07
Evaluation and management of patients with isolated neutropenia.
Pediatr Blood Cancer, 2019 Jul 24
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).
Haemophilia, 2020 Aug 3
WFH Guidelines for the Management of Hemophilia, 3rd edition.
Blood, 2012 Mar 12
How we choose factor VIII to treat hemophilia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
Lancet (London, England), 2010-12-11
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Blood, 2012 Apr 04
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.
Clin Lymphoma Myeloma Leuk, 2019 Sep 30
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Bone Marrow Transplant, 2018 Jun 08
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
Semin Hematol,
Epidemiology and risk factors for venous thrombosis.
Blood, 2016-07-14
How I treat patients with inherited bleeding disorders who need anticoagulant therapy.
Blood, 2016 Sep 26
New concepts for anticoagulant therapy in persons with hemophilia.
Transplant Cell Ther, 2021 Sep 02
Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Blood Adv,
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
Front Oncol, 2021 Mar 25
TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia.
Regen Ther, 2020 May 15
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.
Transfusion, 2020 Sep 24
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Lancet Haematol,
Management of anticoagulant-refractory thrombotic antiphospholipid syndrome.
Lancet (London, England), 2016-02-13
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Blood, 2019-06-06
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
Eur J Haematol, 2021 Feb 17
Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-10
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Journal of pediatric hematology/oncology, 2019-08
Impact of IgG Monitoring and IVIG Supplementation on the Frequency of Febrile Illnesses in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Maintenance Chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-20
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Blood, 2016-11-24
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Lancet, 2012 Apr 04
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Blood, 2018 Aug 30
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
British journal of haematology, 2008-06
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
Leukemia, 2021 May 03
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
N Engl J Med,
Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
Transfusion, 2017 May 03
From total blood exchange to erythrocytapheresis and back to treat complications of sickle cell disease.
Autoimmun Rev, 2017 Sep 09
Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?
Cancer Cell, 2020 Oct 08
Open Notes in Oncology: Patient versus Oncology Clinician Views.
J Gen Intern Med, 2021 Feb 02
Words Matter: What Do Patients Find Judgmental or Offensive in Outpatient Notes?
JAMA Netw Open, 2020 Jun 01
Frequency and Types of Patient-Reported Errors in Electronic Health Record Ambulatory Care Notes.
Practical radiation oncology, 2019-03
Impact of Open Access to Physician Notes on Radiation Oncology Patients: Results from an Exploratory Survey.
Br J Haematol, 2013 Aug 02
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Blood Adv, 2020 Jan 28
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Blood, 2019 Apr 25
Transfusion-related red blood cell alloantibodies: induction and consequences.
J Clin Med, 2020 Nov 23
Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes.
Am J Hematol, 2012 May 28
Genetic modifiers of sickle cell disease.
Blood, 2008-02-15
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Blood, 2016-07-28
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood advances, 2016-12-27
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
The Lancet. Haematology, 2018-12
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
N Engl J Med,
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04
Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Pediatr Blood Cancer, 2019 Jul 31
Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia.
J Clin Oncol, 2021 Dec 9
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Blood Cancer Discov, 2021 Dec 01
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
Circulation, 2022 Nov 06
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Circulation, 2022 Nov 06
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
Lupus, 2021 May 27
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome.
American journal of hematology, 2020 Dec 08
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Blood cancer journal, 2023 Oct 11
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Journal of the National Medical Association, 2009-10
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
Blood,
Reproductive issues in sickle cell disease.
Ann Oncol,
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.
Lancet,
Activation of coagulation system during air travel: a crossover study.
Eur J Dermatol,
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series.
Am J Hematol, 2019 Aug 07
The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
Exp Hematol Oncol, 2021 Feb 19
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.
Clin Microbiol Infect, 2018 Feb 07
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
The Lancet. Haematology, 2019-03
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
J Clin Oncol, 2021 Dec 02
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Urology, 1982-09
Prevention of cyclophosphamide-induced hemorrhagic cystitis.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-03
Intravesicular cidofovir for the management of BK virus-associated cystitis.
Clin Infect Dis, 2005 Jan 21
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.
Pediatr Transplant, 2014 Sep 08
Successful treatment of hemorrhagic cystitis after hematopoietic stem cell transplantation with intravesical hyaluronic acid.
J Clin Oncol, 2021 Apr 30
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Pediatr Infect Dis J, 2014 Nov
Effective treatment of severe BK virus-associated hemorrhagic cystitis with leflunomide in children after hematopoietic stem cell transplantation: a pilot study.
Bone Marrow Transplant, 2006 Mar
Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation.
Blood, 2006-05-01
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Blood, 2017-03-09
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
The Lancet. Oncology, 2015-10
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
N Engl J Med, 2013 Jul 11
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Blood, 2012 Jun 19
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Genetic epidemiology, 2016-09
Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project.
American journal of hematology, 2019-03
Neutropenia in the age of genetic testing: Advances and challenges.
Blood, 2021 Jan 07
When non-Whiteness becomes a condition.
Blood, 2019-04-11
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Blood, 2013-08-01
Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review.
Circulation, 2003 Jun 17
The epidemiology of venous thromboembolism.
Haematologica, 2007 Feb
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
PLoS One, 2015 Dec 30
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Int J Lab Hematol, 2021 Oct 05
A single-institution retrospective study of causes of prolonged prothrombin time and activated partial thromboplastin time in the outpatient setting.
Pediatr Blood Cancer, 2021 Oct
Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
J Clin Pharmacol, 2021 Jul 16
Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
J Clin Oncol, 2022 Dec 19
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Blood, 2018 Apr 5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood Adv, 2021 Aug 24
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Pediatric blood & cancer, 2011-01
Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.
British journal of haematology, 1987-05
Thalassaemia intermedia: interaction of the triple alpha-globin gene arrangement and heterozygous beta-thalassaemia.
Blood, 1983 Nov
A family with segregating triplicated alpha globin loci and beta thalassemia.
Klin Wochenschr, 1991 Oct 02
Interaction of heterozygous beta (0)-thalassemia and triplicated alpha globin loci in a Swiss-Spanish family.
Hemoglobin, 1992
A new case of thalassemia intermedia: interaction of a triplicated alpha-globin locus and beta-thalassemia trait.
Blood, 2014 Apr 16
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
J Clin Oncol, 2018 Mar 02
IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
N Engl J Med, 2009 Jan 07
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Front Oncol, 2020 Jul 16
Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia.
Leukemia, 2021 Jun 26
DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Haematologica, 2021 Nov 01
Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia.
Journal of palliative medicine, 2012-11
Conceptual models for integrating palliative care at cancer centers.
Nature reviews. Clinical oncology, 2016-03
Integrating palliative care into the trajectory of cancer care.
Blood, 2003 Mar 27
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.
N Engl J Med, 2019 Sep 19
Anemia of Inflammation.
Am J Med, 1990 Mar
Diagnosis of iron-deficiency anemia in the elderly.
Hepatology, 1996 Jun
Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure.
Hepatology, 1986 Jul-Aug
Multivariate analysis of prognostic factors in fulminant hepatitis B.
Gut, 1992 Jan
Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators.
Blood, 2018 Sep 10
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
Hematology. American Society of Hematology. Education Program, 2015
Coagulopathy in liver disease: a balancing act.
British journal of haematology, 2015-10
A pilot randomized trial of red blood cell transfusion for acute treatment of vaso-occlusive pain episodes in sickle cell anaemia.
Hered Cancer Clin Pract, 2021 Apr 01
Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
Seminars in hematology, 2002-04
Chronic neutropenia associated with autoimmune disease.
Blood, 2002 Jan 01
Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B.
Ther Adv Musculoskelet Dis, 2020 Nov 24
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.
Pediatric blood & cancer, 2019-08
Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children.
Haematologica, 2019 Jan 03
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
N Engl J Med,
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
The New England journal of medicine, 1994-03-17
High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.
Haematologica, 2013-09
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.
JAMA, 2021 Mar 02
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
American journal of hematology, 2024 Feb 05
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Blood Adv,
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Radiother Oncol, 2021 Dec 7
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Int J Radiat Oncol Biol Phys, 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Int J Radiat Oncol Biol Phys, 2022 Dec 20
Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.
Transplant Cell Ther, 2022 Dec 30
Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Blood advances, 2020 Jul 28
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26
Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Blood advances, 2020 Nov 24
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Journal of the National Cancer Institute, 2013-08-21
Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.
Journal of the National Cancer Institute, 2018-01-01
Use of Alternative Medicine for Cancer and Its Impact on Survival.
JAMA oncology, 2021 May 01
Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors: The PEACE Randomized Clinical Trial.
Antioxidants & redox signaling, 2020 Aug 07
Vitamin C and Cell Death.
Journal of experimental & clinical cancer research : CR, 2020 Oct 07
Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas.
BMJ (Clinical research ed.), 2000 Nov 04
The role of complementary and alternative medicine.
N Engl J Med, 2018 Jul 19
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
N Engl J Med, 2019 Aug 8
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
American journal of hematology, 2022 Sep 08
HbSC disease: A time for progress.
Journal of hospital medicine, 2019-01
Things We Do for No Reason: Intermittent Pneumatic Compression for Medical Ward Patients?
The New England journal of medicine, 2019 Feb 18
Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.
Phlebology, 2020 Mar 02
Risks and contraindications of medical compression treatment - A critical reappraisal. An international consensus statement.
VASA. Zeitschrift fur Gefasskrankheiten, 2001 Jul
Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation.
Journal of vascular surgery, 2000 Nov
Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin.
JCO precision oncology, 2023 May
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements.
J Hematol Oncol, 2022 Mar 26
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
Blood advances, 2022 May 10
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.
Pediatric blood & cancer, 2015-06
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Leukemia & lymphoma, 2018-08
Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Haematologica, 2016 Mar
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
Bone marrow transplantation, 2020 Dec 07
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).
Circulation. Cardiovascular interventions, 2015-10
Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction: Systematic Review and Meta-Analysis.
Research and practice in thrombosis and haemostasis, 2018 Oct 19
May-Thurner syndrome and thrombosis: A systematic review of antithrombotic use after endovascular stent placement.
Thrombosis and haemostasis, 2019 Oct 28
Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome.
Journal of thrombosis and haemostasis : JTH, 2021 Apr 01
Pediatric May-Thurner Syndrome-Systematic review and individual patient data meta-analysis.
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Journal of medical case reports, 2014 Mar 04
Cytomegalovirus-associated splenic infarcts in an adult immune-competent man: a case report and review of the literature.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
N. Engl. J. Med.,
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med,
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Blood, 2009 Mar 10
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 01
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
The New England journal of medicine, 2023 Dec 12
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal of oncology practice, 2018-09-04
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.
Leukemia & lymphoma, 2022 Mar 15
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Hematology. American Society of Hematology. Education Program, 2020 Dec 04
Updates in infection risk and management in acute leukemia.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
Archives of drug information, 2008-12
A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.
Bone marrow transplantation, 2003 Jul
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Leukemia, 2005 Apr
Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation.
Transplantation and cellular therapy, 2021 Oct 02
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.
Blood, 2021 May 13
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
J Clin Oncol, 2022 Jul 22
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
The New England journal of medicine, 2022 Jul 13
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Medicina oral, patologia oral y cirugia bucal, 2008 Oct 01
Malignant mental nerve neuropathy: systematic review.
Blood, 2023 Mar 23
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.
Blood advances, 2020 Jun 23
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Related Topics in Hematology

Copyright © 2024 theMednet
All Rights Reserved.